BioVex Raises $40 Million
BioVex Inc., a Woburn, Mass.-based drug company whose lead candidate is designed to help treat advanced melanoma, has raised $40 million in a first close of its Series F round. Forbion Capital Partners led the round, and was joined by return backers including Credit Agricole Private Equity, Harris & Harris Group, Innoven Partners, New Science Ventures, Triathlon Medical Venture Partners and Scottish Equity Partners. The company previously raised around $110 million.
30 March 2009•3 mins read
